TrialJournal of the European Academy of Dermatology and Venereology : JEADV2017

Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.

A Blauvelt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.